There has been a growing opioid crisis in the United States and Canada. The aim of this study was to analyze trends in opioid-related deaths from the Eastern Ontario Regional Forensic Pathology Unit so that prevention strategies for these deaths can be developed. The analyses included examining the opioids involved and demographic characteristics of the individuals in these deaths so that possible risk factors for opioid-related deaths could be identified.
INTRODUCTION
Canada is the second largest consumer of opioids per capita in the world, with the United States the largest user (1) . The United States consumed almost all hydrocodone, 99.1% of all world consumption in 2016, with Colombia and Canada being other users. Hydromophone was also being used mostly in the United States (49.3% of global consumption) and Canada (27.8%). The United States was the most frequent user of all oxycodone (72.9%) with Canada the second highest user. Just over half of all morphine (50.6%) was consumed in the United States, with Canada consuming 6.8%; however per capita, more morphine is consumed in Canada than the United States. Finally, the United States consumed 29.9% of all licit fentanyl, with Canada consuming 4.6% (1) .
Over the past decade, there has also been an increase in the number of opioid prescriptions. A study by Health Quality Ontario, using data from the Narcotics Monitoring System, found that people in Ontario filled more than nine million prescriptions for opioids in 2015/16, an increase of nearly 450 000 prescriptions from the previous three years (2) . According to Statistics Canada, a survey conducted in 2017, found that 29% of Canadians aged 18 years or older have reported using some form of an opioid in the last five years (3) . With the availability of opioids and their increased use, it should come as no surprise that there has been an increase in opioid-related mortality. Gomes and colleagues in their report on The Burden of Premature Opioid-Related Mortality, found that in the 5935 opioid-related deaths in Ontario, from 1991 to 2010, the overall rate of opioid-related mortality increased by 242% (4).
The research and publications examining factors contributing to increased mortality in opioid-related deaths in Canada and the United States is not lacking, a definitive simple solution to curtail the problem however has not been found. In a systemic review of possible determinants contributing to the increased mortality, King and colleagues concluded that diverse and regionally variable determinants were at play. Prescriber behavior, user behavior and characteristics, and environmental and systemic determinants all played a role in the increasing number of opioid-related deaths. These determinants could vary according to time, geography, and population (5) .
The aim of this study was to analyze trends in opioid-related deaths, the opioids involved in the deaths, and the demographic characteristics of the individuals involved in these deaths from the Eastern Ontario Unit, which provides Forensic Pathology services to a population of approximately 1.4 million people, from 2011 to 2016. The analysis was designed to assess whether unique trends in opioid deaths were present in this region of Ontario. Finding any unique trends could then be applied to reduce opioid-related mortality. It should be noted that Ontario residents are covered by the Ontario Health Insurance Plan (OHIP); this allows residents to access routine and emergency medical care free of charge at the point of use. While OHIP does not cover prescription drugs, many residents have private insurance plans that cover these costs. Seniors' prescription drugs are paid by the Ontario Drug Benefit program.
METHODS
A retrospective cross-sectional analysis of the full autopsy and toxicology data between 2011 and 2016 was undertaken to examine the opioid-related death trends of the Eastern Ontario Unit. An electronic search of the unit's electronic database using the key words: toxicity, poisoning, and intoxication in the cause of death statement was done. Records were then selected if one or more opioid drugs were part of the cause of death statement previously determined by the unit's Forensic Pathologists. One case was eliminated as the decedent had been successfully resuscitated following drug use and died in hospital after several days of hospitalization. Admission samples were not available for testing, thus opioid and other drug use could not be confirmed. Four other cases were removed as therapeutic administration of opioids was identified. One additional case was removed as it was not from Ontario. Finally, all drug toxicity-related deaths associated with medical assistance in dying were also excluded. The total number of cases that were examined was 274. 
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Data were coded according to the case assigned autopsy number to uphold confidentiality. Information gathered included: autopsy number, year and month of death, cause of death, presence of drug paraphernalia at the scene as noted in the autopsy report, and the drugs present at death according to the toxicology report. Demographic characteristics available included: height, weight, age, and gender. Manner of death was separately retrieved from the Provincial Coroners' Information System database.
We analyzed the opioid(s) present at death from 2011 to 2016. Analyses of the number of opioids contributing to death (either single or multiple) were performed. Certain nonopioid drugs reported in the toxicology reports were also examined. We explored the trends in opioid-related deaths by year and age-group, the distribution of opioid-related deaths by age-group and manner of death and examined the percentage of death by manner according to gender. Age groups were set as <14, 15 to 24, 25 to 34, 35 to 44, 45 to 54, 55 to 64, and > 65 years. This age stratification and several of the analyses performed followed methodology described by Gomes and colleagues (6) so that we could compare Eastern Ontario data with other studies examining opioid-related deaths in the province of Ontario.
Descriptive statistics were used to summarize demographic information. Linear regression analysis was used to test for a significant trend in the number of deaths, between 2011 and 2016. Z tests were used to compare two proportions. A type I error of 5% was used as the threshold for statistical significance; analyses were conducted using Microsoft Excel for Mac, version 15.23 and Minitab 16.
RESULTS
Two-thirds (66%) of individuals who died of opioid-related deaths from 2011 to 2016 were male. The age ranged from 16 to 91 years, with a mean and median age of 43 and 43.5 years, respectively ( Table 1) . Of the 274 opioid-related deaths investigated, 195 (71%) were determined to be accidents, 57 (21%) were suicides, and 22 (8%) were undetermined. There were no opioid-related homicides during the period examined.
The number of opioid-related deaths during the time period examined ranged from 39 to 55 deaths per year (Tables 2 and 3) , with the highest number of deaths occurring in 2015. Overall, the number of opioid-related deaths during this time period increased (P = .04). Less than half of all opioid deaths from 2011 to 2016 involved only a single opioid (38%; Table 2 ). The most common opioid involved in this group was fentanyl, followed by morphine, hydromorphone, oxycodone, and methadone. Although the number of deaths from each opioid changed over the six years examined, none showed a significant increase or decline during the time period. Heroin and hydrocodone accounted for a small number of deaths during the six years. Tramadol and codeine were not involved in any single opioid-related deaths ( Table 2) .
Of all, 62% of cases were identified as having multiple opioids causing death according to the cause of death statement ( Table 3) . In decreasing order, the most common opioids involved were fentanyl, morphine, hydromorphone, oxycodone, methadone, and codeine. This list reflects the pattern seen when only one opioid was listed in the cause of death. Hydromorphone prevalence within the multiple-opioid deaths increased steadily over the six year period. It played a role in only one death in 2011, then increased steadily, peaking in 2016 where it contributed to 11 deaths that year. Hydromorphone was the only drug in the multiple opioid category that demonstrated a Downloaded from www.afpjournal.com by an AFP Journal subscriber This article is for personal use only and may not be shared or distributed in any fashion ORIGINAL ARTICLE statistically significant increase over the time period (P = .001; Table 3 ).
Examining the toxicology reports allowed analysis of all the opioids present and not just those reported in the cause of death statements as reported above. The toxicology results are depicted in Figure 1 and showed that morphine was the most commonly found opioid. In 2011 it was reported in 19 of the 42 cases that year. The next most prevalent opioids in 2011 were oxycodone (7) and codeine (7), followed by fentanyl (8) . The presence of morphine in 2012 decreased by almost 50% (from 19 to nine cases), whereas fentanyl increased by 50% (ten to 15 cases); the following year these two drugs then switched to a prevalence similar to that of 2011. Hydromorphone's presence at time of death steadily increased over the time period studied, rising from seven to 15 cases from 2011 to 2016; it was the only drug to demonstrate a statistically significant trend (P = .001). The presence of hydrocodone, 6-monoacetylmorphine, tramadol, and oxymorphone were relatively low during the study period. U-47700 was not identified in this jurisdiction until 2016, when it was identified in two cases and listed in the cause of death in both (Figure 1 ). Β-hydroxythiofentanyl and furanyl fentanyl were the only fentanyl analogues found during the study period, each being found and attributed to one death ( Tables 2 and 3 ).
Opioid-related deaths commonly had other drugs present at time of death. In addition to the lethal opioid(s), 222 (81%) of these decedents had one or more stimulant, hypnotic, or antidepressant detected in their toxicological analysis. Antidepressants and their me-6-MAM = 6-monoacetylmorphine, used to identify the presence of heroin HydroM= Hydromorphone HydroC= Hydrocodone *Beta-Hydroxythiofentanyl † Meperidine ‡ U-47700 identified in cause of death. Examining opioid deaths by age-group revealed that there were no opioid-related deaths in those aged of 0 to 14 years. Those aged 45 to 54 years were more frequently dying of opioid deaths compared to the other age groups (Figure 2) . The two groups aged 55 and older each demonstrated a statistically significant increase in their numbers over the time period (P = .01 for those aged 55-64; P = .04 for those aged 65+ years). In contrast, those aged 15 to 24 years had a statistically significant decrease in the number of deaths during the same time period (P = .05).
As described previously, accidents were the most common manner of death (71%), followed by suicides (21%), then undetermined deaths (8%). Stratifying manner of death by age revealed that accidents were the most common manner of death in all age groups except those aged 65 years and older where suicides were more common. When stratified by gender, males had a similar prevalence of accidents (P = .7), suicides (P = .4), and undetermined deaths (P = .5) compared to females (Figure 3) . Note . These values were restricted to the drugs that caused death. 6-MAM = 6-monoacetylmorphine. HydroM= Hydromorphone. HydroC= Hydrocodone. * Other refers to the presences of other drugs not listed in the table being identified as part of cause of death. If a case had more than one drug that qualified as "other" it was only counted once in the "other" category. † U-47700 and Furanylfentanyl listed in the cause of death. 
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DISCUSSION
In 1992, the opioid-related death rate in Ontario was 1.2 per 100 000 population. This has steadily increased since then and in 2010 the rate of opioid-related deaths in Ontario was 4.2 per 100 000 (4). In 2016, it had grown to 6.2 per 100 000, there being 867 cases with a recorded population of almost 14 million (9). In comparison, in the United States in 2016 there were 63 632 overdose deaths, with 42 249 of them opioid-related deaths, which is a rate of over 13.1 per 100 000 (10, 11) . In 2017, the number of opioid deaths in the United States was over 70 000 (8) .
In 2016, the population in the Eastern Ontario health care region (Champlain Local Health Integration Network [LHIN]) was 1 334 963, with just under one million living in the city of Ottawa. The Eastern Ontario Unit covers a slightly larger population of around 1.4 million. Based upon our data, the 2016 death rate from opioid-related toxicity was 3.5 per 100 000. This is lower than the overall Ontario rate. The highest rates in Ontario were in the more sparsely populated northern parts of the province.
Why our region of the Province is somewhat protected from opioid deaths was not revealed in our study alone ORIGINAL ARTICLE but can be explained when interpreted in the context of previously reported data. Opioid prescribing practices have been shown to vary geographically (7, 12, 13) . In addition, opioid prescribing practices have also been found to be linked to opioid-related mortality (9, 14, 15) . Active opioid prescriptions among decedents, high volume prescribing among decedents' physicians, high-dose opioid therapy, and high volume of sales of opioids have all been associated with opioid-related mortality (9, (14) (15) (16) (17) (18) (19) (20) . In an Ontario study, published in 2011, the association between opioid prescribing and opioid-related mortality in Ontario was examined; in addition, the authors also looked at the geographical variations of these measures (21) . In their map of Ontario, the Champlain LHIN had lower annual opioid prescription rates per 1000 population relative to other areas in the province (21) . They found a significant association between county level opioid prescribing rates and opioid-related mortality. The low regional prescribing practices could explain our region's lower opioid mortality rate when compared to other areas of the province.
In our study, the mean age was 43 years with a median age of 43.5 years. Those aged 45 to 54 years were more frequently dying of opioid deaths compared to the other age groups. The two groups aged 55 and older each demonstrated a statistically significant increase in their numbers over the time period (P = .01 and P = .04); those aged 15 to 24 however had a decrease in the number of deaths during the study period (P = .05). Two-thirds of the individuals in our study were men. The characteristics of our study group are similar to those reported for the entire province. In a study examining trends in opioid-related deaths in Ontario in 2015, two-thirds were male and the average age at the time of death was 43 years (6).
The majority of deaths in our study were classified as accidental (71%) highlighting the potential preventability of these deaths. Suicides were more common than accidents in patients 65 and older, potentially suggesting a decreased quality of life and indicating different prevention strategies for this group. When stratified by gender, males and females had similar 
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rates of suicides, accidents, and undetermined manners of death. In the Ontario study, accidental deaths were reported in a slightly higher proportion of cases at 83%; they too reported a high percentage of opioid-related suicidal deaths in those aged 65 years and above (6) .
In our study, less than half of the opioid-related deaths involved a single opioid (38%); in contrast, the Ontario study reported a majority of their opioid-related deaths (58%) were attributed to a single opioid (6) . In our study, opioid-related deaths from a single opioid and from multiple opioids both demonstrated the same pattern of opioid responsible for death: in decreasing order, the most common opioids involved were: fentanyl, morphine, hydromorphone, oxycodone, and methadone. Fentanyl's strong potency would account for its prevalence in both single-and multiple-opioid deaths.
Examining the toxicology reports for all drugs showed that morphine was the most commonly found opioid. Hydromorphone's presence at time of death steadily increased over the time period studied; it was the only drug to demonstrate a statistically significant trend (P = .001). This trend is not surprising giving its increasing presence in both single and multiple opioid-related deaths. Oxycodone was found less frequently at time of death over the study period; this decline however was not statistically significant (P = .09). The latter's 
lack of statistical significance may be explained by the small numbers of cases seen once the data was broken down by year.
In Ontario, the type of opioid attributed to death has also changed. The main change provincially has been a decrease in the rate of oxycodone-related deaths and an increase in fentanyl and hydromorphone-related deaths. In 2005, oxycodone was the opioid involved in the highest number of opioid-related deaths in Ontario; in 2014, however, fentanyl surpassed oxycodone to become the opioid most commonly involved. The authors of that study attributed the decrease in oxycodone to the introduction of a tamper-deterrent formulation of long-acting oxycodone in 2012. Despite the new formulation, however, the overall rate of opioid-related deaths did not decrease but actually increased. This led the authors to conclude that tamper-deterrent formulations would have limited impact on opioid-related adverse events and instead simply cause a shift in the type of opioid(s) used (6) . Interestingly, the opposite trend occurred when long-acting 
oxycodone was added to the provincial drug formulary in 2000. Examination of opioid-related deaths before and after the introduction of long-acting oxycodone found an increase in prescriptions for oxycodone as well as an increase in prescriptions of opioid analgesics. During the same time period, opioid-related deaths doubled and there was a five-fold increase in oxycodone-related mortality (22) . Thus changes in drug formulation have not been effective in curtailing opioid-related deaths.
One feature that has consistently been shown, in this and other studies looking at drug-related deaths, is polydrug use (5, 6, 9, 15, 19, 22, . Studies report the presence of antidepressants, benzodiazepines, other hypnotics, alcohol, and illicit drugs in opioid deaths. Our study found a significant proportion of decedents (81% overall) demonstrated use of other drugs. Antidepressants and their metabolites (48%), hypnotics (47%), and stimulants (31%) were all identified in the toxicological analysis of the 274 cases analyzed. In the Ontario study, Gomes and colleague found similar results; 47%, 51%, and 32% of their cases had the presence of antidepressants, benzodiazepines, and cocaine, respectively (6). 
Having several central nervous system, depressant drugs present logically places an individual at risk for death. The underlying reason(s) why these other drugs have been previously prescribed, however, is not clear and merits discussion. With nearly half of our opioid-related deaths demonstrating the presence of antidepressants or hypnotics, one possibility is that there is a high percentage of mental health comorbidity in this population, thus suggesting that mental health issues is a risk factor for opioid-related deaths. Another possibility is that these patients had been prescribed these medications for the treatment of chronic pain. A consensus statement and guidelines from the Canadian Pain Society recommended tricyclic antidepressants and anticonvulsants (gabapentin and pregabalin) for first-line treatment, and serotonin noradrenalin reuptake inhibitors and topical lidocaine as second-line treatments for chronic neuropathic pain (27) 
recommended the same medication as first-line treatment options (28) . Finally, in a joint clinical practice guideline from the American College of Physicians and the American Pain Society, tricyclic antidepressants were listed as an option for pain relief in patients with chronic low back pain (29) . These guidelines suggest that the presence of some of these drugs may in fact be for the treatment of chronic pain. In an Ontario-based study that examined characteristics of opioid users whose death was related to opioid toxicity, 25% of those studied had been diagnosed with depression, 10% with another psychiatric condition (attention deficit disorder, obsessive-compulsive disorder, bipolar, or schizophrenia), and 37% were reported as having chronic pain (23) . Polydrug use therefore may not be due to one cause or seen in a homogenous population, but is likely due to several different reasons affecting different risk groups. Prevention strategies therefore will need to address more than one group; patients with depression and chronic pain appear to make up a significant proportion of those at risk of opioid toxicity.
The rise in the use of fentanyl and fentanyl analogs has been noted in opioid-related deaths in North America along with other opioid analogs, such as U-47700 (30, 31) . In a study analyzing overdose deaths with fentanyl and fentanyl analogs in New York City between 2000 and 2017, there was a sharp increase in fentanyl-related deaths between 2014 and 2017 with a 3000% increase. Fentanyl was present in 57% of overdose deaths (31) . Fentanyl analogs were only encountered in a limited number of cases in our series. Carfentanil was not encountered in this study, but has been seen since. The authors of the New York study point out that national US data are limited by a lack of drugs being recorded on death certificates and lack of standardized toxicology testing (31).
Our study was restricted to a specific area in Ontario, as such there are strengths and limitations associated with the study. A strength of the study was that the cause of deaths were all based on full postmortem examination and toxicology reports and not restricted to death certificate data alone. With this, more detailed toxicological information, not just the drugs attributed to the death, were evaluated. This allowed us to look at other drugs present at time of death and identify populations at risk of opioid deaths. The certifications were performed by a small group of four forensic pathologists working together. Certification practices would subsequently be more uniform than a larger group of certifying physicians with varying levels of training. A study weakness was that we were unable to discern prescribed versus illicit use of opioids and other drugs. The presence of drug paraphernalia at the scene would indicate potential illicit opioid use; that information however was not always available so it was not included in the analyses. Demographic characteristics available did not include socioeconomic status, ethnicity, level of education, religion, and occupation of the decedent. This information could have provided further understanding into the individuals dying of opioid use and potential routes of intervention.
CONCLUSION
In conclusion, the number of opioid-related deaths in Eastern Ontario increased from 2011 to 2016. The typical victim was a male in his forties with polydrug use. Lower annual prescribing rates in our region appear to be associated with a lower regional opioid mortality rate when compared to elsewhere in the province. The type of opioid involved in opioids overdoses changed indicating that interventions should not focus exclusively on one opioid. There was no significant decrease in the number of deaths associated with oxycodone despite the introduction of a tamper-resistant formulation in Ontario in 2012. Accidental deaths were the most common manner of death, underlining the preventable nature of these deaths. The presence of prescription drugs, particularly antidepressants and benzodiazepines indicates these people have had contact with health services. Those at risk may include individuals with previously diagnosed mental health status and/or underlying chronic pain. In the elderly, suicide was the most common manner of death.
The data suggest prevention strategies should aim at health-care providers who see these individuals. Persons who are coprescribed antidepressants and benzodiazepines with opioids should be cautioned regard-
